SLXN Initiates Phase 2/3 Trial
SLXN starts phase 2/3 trial for SIL204
Story updates
11:01:54 AM UTC
SquawkNews
SLXN Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.